|

MindMed Joins the NASDAQ : MindMed Stock Analysis & Prediction (MMED / MMEDF)

MindMed has officially been added to the NASDAQ Global Market.
On April 22nd, MindMed filed an 8-A12B with the SEC which ultimately allowed it to uplist to the NASDAQ. For NEO owners, the ticker symbol will remain MMED, for OTC owners, it’ll change to MNMD.

On 23rd of April, MindMed announced that as onf April 27th MindMed will be trading as MNMD on the NASDAQ. This means that MindMed was able to meet financial and listing requirements. Typically when securities get listed on major stock exchanges, they are highly traded and prices higher than those that trade OTC. Being able to uplist and trade on an exchange such as the NASDAQ will provide MindMed exposure and visibility to a larger market which might, in the short term, 2, 3 or 4x MindMed’s stock price as more people buy the stock due to FOMO. This happened when Compass Pathways IPOed which almost 4xed its share price within a few days from $17 to $60 before CMPS dropped back down to $33.

Where does MindMed go from here on? MMEDF is just at the beginning of their long-term growth trajectory. Some investors might feel inclined to take profits, which is absolutely understandable. However, like I’ve been saying in the majority of my MindMed episodes or any psychedelic stock videos, the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedNasdaq #MindMedstock

Similar Posts

  • Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT

    In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).

    Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting. 

    Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.

    Excitingly, Mindset is moving towards beginning clinical trials in 2022.

    On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs. 

    In the long term, this deal has great potential for Otsuka. 

    To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:

    Can psychedelics treat mental illnesses such as depression?

    Are next-generation psychedelics better than the originals?

    What is happening in the brain when a person takes psychedelics?

    Enjoy the episode!

    You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

    *To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/

    #MindsetPharma #DMT #microdosing

  • Can Ketamine Treat Depression? Meet Delic, the LARGEST Ketamine Clinic Company

    In today’s episode, I talk with Matt Stang, CEO of Delic Corp. Delic (OTCMKTS: DELCF) is a psychedelic medicines company aiming to put a dent in the mental health crisis.
    They are doing this in three ways.

    First, through their ketamine clinics. Delic runs the largest ketamine network in the world, with dozens of clinics across North America. At the moment, these clinics are only providing ketamine therapy for disorders like depression, but in the future, once they become legal, Delic also plans on offering other psychedelic therapies such as psilocybin and MDMA therapy.

    Second, through education. Delic runs multiple media platforms, such as RealitySandwich.com. These media platforms aim to educate and entertain, leading towards the destigmatization of psychedelics in our culture. As many of the people behind Delic Corp were behind the legendary High Times Magazine, this is an area of expertise for the company. Ultimately, psychedelic compounds will never succeed as medicines if society does not get behind them. Delic also has podcasts, and they host psychedelic medicine events.

    And third, through science. Delic Labs is currently working on creating next generation psychedelics. Delic Labs also works with third parties, completing research, which allows the labs to run on a profit.

    Taken together, Delic is not only a core player in the psychedelics movement, but they are also one of the companies making a solid revenue.

    Enjoy the episode!
    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Video editing: @themyaholy @Psy_holy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. Psychedelic Spotlight and The Psychedelic Investor were hired for this video, on December 3rd, 2021, to publicly disseminate information about (DELIC CORP) via digital communications. We have been paid ($2000 CAD).

    #Delic #Psychedelics #Ketamine

  • Numinus CEO Discussion: a LEADER in Psychedelic-Assisted Therapy? ( NUMI / LKYSF Stock)

    Numinus Wellness (TSX.V: NUMI), (OTC: LKYSF), has been a constant topic of conversation on this channel. NUMI is a company working on psychedelic-assisted therapy: with MDMA for PTSD, in collaboration with MAPS; Ketamine Therapy for Depression; and Psilocybin therapy for addiction, That’s why we decided to invite NUMI’s CEO, Payton Nyquvest. I hope you all enjoy!

    Timestamps
    1:00 – What is Numinus’ mission?
    2:37 – Numinus’ partnership with MAPS to treat PTSD with MDMA
    9:54 – Numinus treating addiction with Psilocybin
    13:35 – Using ketamine to treat Depression
    18:45 – Growing natural Psilocybin vs Synthetic versions?
    21:45 -The 5-year plan
    26:38 – What will revenues look like?

    Enjoy the episode!

    Check out our website:
    ThePsychedelicInvestor.com

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Numinus #NUMIStock
    #numinus #numi #numistock